Current trends in non–HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease
Reads0
Chats0
TLDR
The changes in LDL-C and non-HDL-C in patients with ASCVD over a 17-year period probably are related to increased treatment with statins, but the changes are too small to be explained by widespread use of high-intensity statins.About:
This article is published in Journal of Clinical Lipidology.The article was published on 2019-07-01 and is currently open access. It has received 13 citations till now. The article focuses on the topics: Population & Cholesterol.read more
Citations
More filters
Journal ArticleDOI
Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors.
Cosmin Mihai Vesa,Loredana Popa,Amorin Remus Popa,Marius Rus,Andreea Atena Zaha,Simona Bungau,Delia Mirela Tit,Raluca Anca Corb Aron,Dana Carmen Zaha +8 more
TL;DR: A profound understanding of intimate mechanisms that generate atherosclerosis in DM and ways to inhibit or delay them are of the utmost importance in a society where cardiovascular morbidity and mortality are predominant.
Journal ArticleDOI
Cholesterol in LDL receptor recycling and degradation
Hui-xian Yang,Min Zhang,Shiyin Long,Qin-Hui Tuo,Ying Tian,Jian-Xiong Chen,Caiping Zhang,Duan-Fang Liao +7 more
TL;DR: It is proposed that a balance between LDLR endocytosis recycling and PCSK9-mediated and IDOL-mediated lysosomal LDLR degradation is responsible for cholesterol homeostasis in the ER.
Journal ArticleDOI
Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?
Alan P. Jacobsen,Inbar Raber,Cian P. McCarthy,Roger S. Blumenthal,Deepak L. Bhatt,Ronan W. Cusack,Patrick W. Serruys,William Wijns,John W. McEvoy +8 more
TL;DR: The totality of recent evidence supports the universal need for lifelong aspirin in secondary prevention for all adults with CCS, particularly in stable older patients who are at highest risk for aspirin-induced bleeding.
Journal ArticleDOI
Methods of Calculating Low-Density Lipoprotein Cholesterol Level.
Journal ArticleDOI
Secular Trends in Risk Profiles Among Adults With Cardiovascular Disease in the United States.
Yumin Gao,Nino Isakadze,Eamon Duffy,Qicong Sheng,Jie Ding,Zane T. MacFarlane,Yingying Sang,Scott T. McClure,Elizabeth Selvin,Kunihiro Matsushita,Seth S. Martin +10 more
TL;DR: In this article , a serial cross-sectional analysis of 6,335 adults with self-reported CVD participating in the National Health and Nutrition Examination Survey from 1999 through 2018, calculated age and sex-adjusted proportions with ideal risk factor attainment.
References
More filters
Journal ArticleDOI
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
TL;DR: A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
Journal ArticleDOI
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone,Jennifer G. Robinson,Alice H. Lichtenstein,C. Noel Bairey Merz,Conrad B. Blum,Robert H. Eckel,Anne C. Goldberg,David Lee Gordon,Daniel Levy,Donald M. Lloyd-Jones,Patrick E. McBride,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Karol E. Watson,Peter W.F. Wilson +15 more
TL;DR: Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2 The goals of the …
Journal ArticleDOI
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone +8 more
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
Journal Article
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
TL;DR: Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations.
Journal ArticleDOI
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Colin Baigent,L Blackwell,Jonathan Emberson,Lisa Holland,Christina Reith,Neeraj Bhala,Richard Peto,Elizabeth H Barnes,Anthony C Keech,John Simes,Rory Collins +10 more
TL;DR: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth.
Related Papers (5)
Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
Archna Bajaj,Dawei Xie,Esteban Cedillo-Couvert,Jeanne Charleston,Jing Chen,Rajat Deo,Harold I. Feldman,Alan S. Go,Jiang He,Edward Horwitz,Radhakrishna R. Kallem,Mahboob Rahman,Matthew R. Weir,Amanda H. Anderson,Amanda H. Anderson,Daniel J. Rader,Lawrence J. Appel,John W. Kusek,James P. Lash,Panduranga S. Rao,Raymond R. Townsend +20 more